Biodistribution, pharmacokinetics, dosimetry of [ 68 Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [ 18 F]F-FDG PET/CT in patients with various cancers

Conclusion[68Ga]Ga-DOTA.SA.FAPi is a promising alternative among the FAPI class of molecules and performed well as compared to standard-of-care radiotracer [18F]F-FDG in the diagnosis of various cancers.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research